33 F.4th 1012
8th Cir.2022Background
- Steven Young and Carl Hewitt developed sleep biometric technology at BAM Labs, which Sleep Number acquired in 2015; they later became consultants to Sleep Number under agreements (Dec. 2017) that assigned inventions within a defined Product Development Scope (PDS).
- The PDS covered inventions "relating to sleep" including "biometric monitoring relating to sleep," but expressly excluded SIDS monitoring and blood-pressure monitoring.
- During the consulting period UDP (Young and Hewitt’s new company) filed a provisional application ('613) in October 2018 for under‑substrate sensors measuring respiration, heart rate, weight — described for medical settings; later UDP filed another provisional ('623) and four additional applications claiming priority to the provisionals.
- Sleep Number sued (July 2020) claiming ownership of the inventions and sought a preliminary injunction barring the defendants from prosecuting or amending the patent applications; the district court granted the injunction.
- Defendants later removed priority claims to the '613 provisional for four later applications; the district court found Sleep Number likely to succeed on the merits, that irreparable harm was likely, and that the balance of harms and public interest favored injunctive relief.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standard for preliminary‑injunction likelihood of success | Sleep Number: "fair chance" standard applies | Defendants: higher "more‑likely‑than‑not" standard should apply | Court: "fair‑chance" standard applies (typical for PI; higher standard reserved for challenging statutes/regulations) |
| Whether inventions fall within the PDS (ownership) | Sleep Number: inventions plainly relate to sleep/biometric monitoring and were ideated during the consulting period | Defendants: later applications were filed after termination and thus outside PDS; some inventions target medical (non‑sleep) uses | Held: Inventions plainly relate to sleep/biometric monitoring; conception likely occurred during consulting period — fair chance Sleep Number will prevail |
| Effect of priority changes and risk of prosecution amendments (irreparable harm) | Sleep Number: defendants could amend claims/respond to Office Actions to narrow scope and undermine Sleep Number’s rights; such harms are not easily reparable | Defendants: future harms speculative; remedies (USPTO requests, continuations) can fix any issues | Held: District court did not clearly err — irreparable harm likely given defendants’ prior priority‑claim amendments and likely Office Actions |
| Balance of harms & public interest | Sleep Number: injunction only delays prosecution; enforces contractual obligations and protects public interest in contract enforcement | Defendants: injunction harms third‑party inventors and improperly broadens relief | Held: Balance favors Sleep Number (delay vs loss); public interest supports enforcing contracts; overbreadth argument forfeited on appeal |
Key Cases Cited
- Dataphase Sys., Inc. v. C L Sys., Inc., 640 F.2d 109 (8th Cir. 1981) (sets four‑factor PI framework)
- Winter v. Nat. Res. Def. Council, Inc., 555 U.S. 7 (2008) (irreparable harm must be likely without injunction)
- ConAgra Foods, Inc. v. Lexington Ins., 21 A.3d 62 (Del. 2011) (Delaware contract‑interpretation principles; plain‑meaning rule)
- Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354 (Fed. Cir. 2014) (priority/35 U.S.C. § 120 continuation/priority principles)
- Bio‑Rad Labs., Inc. v. Int’l Trade Comm’n, 996 F.3d 1302 (Fed. Cir. 2021) (distinguishing when employee ideas were not sufficiently concrete to be employer’s)
- Medicine Shoppe Int’l., Inc. v. S.B.S. Pill Dr., Inc., 336 F.3d 801 (8th Cir. 2003) (public interest supports enforcing contractual obligations)